Quantification of the prentice criteria for surrogate endpoints

Biometrics

Volumn 62, Issue 1, 2006, Pages 297-300

  O'Quigley, John ^a   Flandre, Philippe ^b  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

Author keywords

Explained randomness; Information gain; Kaplan Meier estimator; Kullback Leibler distance; Predictive ability; Proportional hazards model; Residuals; Surrogate endpoint

Indexed keywords

EXPLAINED RANDOMNESS; INFORMATION GAIN; KAPLAN-MEIER ESTIMATORS; KULLBACK-LEIBLER DISTANCE; META-ANALYSIS; PREDICTIVE ABILITIES; PROPORTIONAL HAZARD MODELS; REDUCTION FACTOR; RESIDUAL; SURROGATE ENDPOINT;

BIOMETRICS;

BIOMETRY;

ARTICLE; BIOMETRY; CENSORSHIP; CONFIDENCE INTERVAL; KAPLAN MEIER METHOD; MEASUREMENT; PREDICTION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; THEORY;

EID: 33645065336     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2006.00538.x     Document Type: Article

References (18)

1. Allison P. D. 1995 Survival Analysis Using the SAS System: A Practical Guide Cary North Carolina SAS Institute
2. Alonso A. Molenberghs G. Burzykowski T. Renard D. Geys H. Shkedy Z. Tibaldi F. Abrahantes J. and Buyse M. 2004 Prentice's approach and the meta-analytic paradigm: A reflection on the role of statistics in the evaluation of surrogate endpoints Biometrics 60 724 728
3. Buyse M. and Molenberghs G. 1998 Criteria for the validation of surrogate endpoints in randomized experiments Biometrics 54 1014 1029
4. Bycott P. W. and Taylor J. M. G. 1998 An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker Controlled Clinical Trials 19 555 568
5. Cox D. R. 1972 Regression models and life tables (with discussion) Journal of the Royal Statistical Society, Series B 34 187 222
6. Decroix G. Chastang C. Fichet D. Asselain B. Lebeau B. Morice V. Lepage T. Babo P. Fabre C. and Rebischung J. L. 1984 Adjuvant immunotherapy with nonviable mycobacterium segmantis in resected primary lung carcinoma Cancer 53 906 912
7. Flandre P. and O'Quigley J. 1995 A two-stage procedure for survival studies with surrogate endpoints Biometrics 51 969 976
8. Flandre P. and Saidi Y. 1999 Letters to the editor: Estimating the proportion of treatment effect explained by a surrogate marker Statistics in Medicine 18 107 115
9. Freedman L. S. Graubard B. I. and Schatzin A. 1992 Statistical validation of intermediate endpoints for chronic diseases Statistics in Medicine 11 167 178
10. Kaplan E. L. and Meier P. 1958 Nonparametric estimation from incomplete observations Journal of the American Statistical Association 53 457 481
11. Kent J. T. 1983 Information gain and a general measure of correlation Biometrika 70 163 173
12. Kent J. T. and O'Quigley J. 1988 Measures of dependence for censored survival data Biometrika 75 525 534
13. Lin D. Y. Fleming T. R. and De Gruttola V. 1997 Estimating the proportion of treatment effect explained by a surrogate marker Statistics in Medicine 16 1515 1527
14. O'Quigley J. and Flandre P. 1994 Predictive capability of proportional hazards regression Proceedings of the National Academy of Sciences of the United States of America 91 2310 2314
15. O'Quigley J. and Xu R. 2001 Explained variation in proportional hazards regression In Handbook of Statistics in Clinical Oncology Crowley John ed 397 409 New York Marcel Dekker
16. O'Quigley J. Xu R. and Stare J. 2005 Explained randomness in proportional hazards models Statistics in Medicine 24 479 489
17. Prentice R. L. 1989 Surrogate endpoints in clinical trials: Definition and operational criteria Statistics in Medicine 8 431 440
18. Xu R. and O'Quigley J. 1999 A measure of dependence for proportional hazards models Journal of Nonparametric Statistics 12 83 107